Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

101. Heparin versus placebo for non-ST elevation acute coronary syndromes. (Full text)

Heparin versus placebo for non-ST elevation acute coronary syndromes. Non-ST elevation acute coronary syndromes (NSTEACS) represent a spectrum of disease including unstable angina and non-ST segment myocardial infarction (NSTEMI). Despite treatment with aspirin, beta-blockers and nitroglycerin, unstable angina/NSTEMI is still associated with significant morbidity and mortality. Although evidence suggests that low molecular weight heparin (LMWH) is more efficacious compared to unfractionated (...) heparin (UFH), there is limited data to support the role of heparins as a drug class in the treatment of NSTEACS. This is an update of a review last published in 2008.To determine the effect of heparins (UFH and LMWH) compared with placebo for the treatment of patients with non-ST elevation acute coronary syndromes (unstable angina or NSTEMI).For this update the Cochrane Heart Group Trials Search Co-ordinator searched the Cochrane Central Register of Controlled Trials on The Cochrane Library (2013

2014 Cochrane PubMed

102. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. (PubMed)

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. The choice of the appropriate perioperative thromboprophylaxis in patients with cancer depends on the relative benefits and harms of low molecular weight heparin (LMWH) and unfractionated heparin (UFH).To update a systematic review of the evidence for the relative efficacy and safety of LMWH and UFH for perioperative thromboprophylaxis in patients with cancer.We performed (...) ), postoperative drain volume (MD= 27mL; 95% CI -44 to 98), and thrombocytopenia (RR 1.33; 95% CI 0.59 to 3.00).We found no difference between perioperative thromboprophylaxis with LMWH versus UFH in their effects on mortality, thromboembolic outcomes, major bleeding, or minor bleeding in patients with cancer. Further trials are needed to evaluate the benefits and harms of different heparin thromboprophylaxis strategies in this population more thoroughly.

2014 Cochrane

103. Heparin versus normal saline for patency of arterial lines. (PubMed)

Heparin versus normal saline for patency of arterial lines. For most patients who require intensive care, the success of clinical decision making and interventions is dependent on the accuracy of different physiological variables measured or obtained from samples using an arterial catheter. Maintaining the patency of these catheters is therefore essential for obtaining accurate measures, minimizing patient discomfort and reducing expenses incurred when an occluded catheter requires replacement (...) . Uncertainty exists amongst clinicians as to best practice surrounding the contents of the arterial catheter flush solution (heparin or saline). The use of heparin is more expensive and is accompanied by significant risks such as haemorrhage, hypersensitivity and heparin-induced thrombocytopenia (HIT).The objective of this review was to evaluate whether normal saline is as efficacious and safe as heparin in maintaining the patency of arterial intravascular catheters in adult patients without

2014 Cochrane

104. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. (Full text)

Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Anticoagulant treatment for intermittent claudication might improve functional capacity and prevent acute cardiovascular complications caused by peripheral obstructive arterial disease. This is an update of the review first published in 2001.To assess the effects of anticoagulant drugs (heparin, low molecular weight heparin (LMWH) and oral anticoagulants) in patients with intermittent (...) patients with intermittent claudication.Seven studies were included. Only three studies (two evaluating oral anticoagulants, one evaluating heparin) met the high quality methodological inclusion criteria and were included in the primary analysis. Four other studies were included in the sensitivity analysis. The authors extracted the data independently.No new studies were included for this update. Seven studies with a combined total of 802 participants were included in this review. No significant

2014 Cochrane PubMed

105. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). (Full text)

Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Venous thromboembolic disease has been extensively studied in surgical patients. The benefit of thromboprophylaxis is now generally accepted, but it is medical patients who make up the greater proportion of the hospital population. Medical patients differ from surgical patients with regard to their health and the pathogenesis of thromboembolism and the impact (...) that preventative measures can have. The extensive experience from thromboprophylaxis studies in surgical patients is therefore not necessarily applicable to non-surgical patients. This is an update of a review first published in 2009.To determine the effectiveness and safety of heparin (unfractionated heparin or low molecular weight heparin) thromboprophylaxis in acutely ill medical patients admitted to hospital, excluding those admitted to hospital with an acute myocardial infarction or stroke (ischaemic

2014 Cochrane PubMed

106. Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty

Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Deep vein thrombosis (DVT) is a blood clot, or thrombus, that forms in a deep vein most commonly in the legs. DVT is serious since

2014 Health Technology Assessment (HTA) Database.

107. Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. (Full text)

Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. The prevalence of children diagnosed with deep vein thrombosis or pulmonary embolism has been increasing in the last decade. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). To date, it is unknown if the practice of anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC-related

2014 Cochrane PubMed

108. Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization. (Full text)

Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization. The role of cardiac catheterization in pediatrics has progressed significantly over the last two decades, evolving from a primary diagnostic tool to a primary treatment modality in children with congenital heart disease. Vascular complications, particularly arterial thrombosis, are among the most common unwanted post-cardiac catheterization events. In 1974, unfractionated (...) heparin proved to be superior to placebo in decreasing the incidence of arterial thrombosis in pediatric patients. However, the optimal dose of unfractionated heparin to be utilized in this setting remains a matter of controversy.To evaluate the use of low-dose (< 100 units/kg) versus high-dose (≥ 100 units/kg) unfractionated heparin administered as an intravenous bolus at the time of initiation of cardiac catheterization (that is, immediately after arterial puncture), with or without subsequent

2014 Cochrane PubMed

109. Heparin-bonded catheters for prolonging the patency of central venous catheters in children. (Full text)

Heparin-bonded catheters for prolonging the patency of central venous catheters in children. Central venous catheters (CVCs) are a mainstay in the management of critically ill children. However, these catheters are associated with mechanical and infectious complications which reduce their life span. Heparin bonding of catheters has shown promise in animal studies and in adults. This is the first update of a review published in 2007.The primary objective was to determine the effect of heparin (...) -bonded CVCs on the duration of catheter patency in children. Secondary objectives were to determine the effects of heparin-bonded catheters on catheter-related thrombosis, occlusion, blood stream infection and side effects.For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). The authors searched MEDLINE (1946 to week 3 August 2013).We included randomized and quasi

2014 Cochrane PubMed

110. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism (...) : a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

2014 Health Technology Assessment (HTA) Database.

111. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety

Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness (...) and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

2014 Health Technology Assessment (HTA) Database.

112. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness

Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT (...) and PE: a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs

2014 Health Technology Assessment (HTA) Database.

113. Citrate Versus Heparin Lock for Hemodialysis Catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials (PubMed)

Citrate Versus Heparin Lock for Hemodialysis Catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials Citrate solution has been suggested as an effective and safe catheter lock in hemodialysis. However, whether a citrate lock is superior to a heparin lock in preventing catheter-related infections and maintaining catheter patency is inconclusive.A systematic review and meta-analysis was performed by searching in PubMed, EMBASE, Ovid, the Cochrane Library, and Web (...) of Science databases and major nephrology journals.Patients receiving hemodialysis with central venous catheters.Randomized controlled trials comparing citrate locks with heparin locks in hemodialysis patients with central venous catheters.Locking central venous catheters with citrate locks.Primary outcomes include catheter-related bloodstream infection (CRBSI), exit-site infection, catheter removal for poor flow, and thrombolytic treatment.13 randomized controlled trials (1,770 patients, 221,064

2014 EvidenceUpdates

114. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati (PubMed)

Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati Heparin-induced thrombocytopenia (HIT) is diagnosed using clinical criteria and detection of platelet-activating anti-platelet factor 4/heparin (anti-PF4/H) antibodies, usually through a surrogate enzyme-linked immunosorbent assay (ELISA

2014 EvidenceUpdates

115. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. (PubMed)

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Bivalirudin, with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of care in primary percutaneous coronary intervention (PPCI). We aimed to compare antithrombotic therapy with bivalirudin or unfractionated heparin during this procedure.In our open-label, randomised controlled trial, we enrolled (...) consecutive adults scheduled for angiography in the context of a PPCI presentation at Liverpool Heart and Chest Hospital (Liverpool, UK) with a strategy of delayed consent. Before angiography, we randomly allocated patients (1:1; stratified by age [<75 years vs ≥75 years] and presence of cardiogenic shock [yes vs no]) to heparin (70 U/kg) or bivalirudin (bolus 0·75 mg/kg; infusion 1·75 mg/kg per h). Patients were followed up for 28 days. The primary efficacy outcome was a composite of all-cause mortality

2014 Lancet

116. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup (Full text)

Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup The hypothesis that endovascular treatment with covered stents has equal risks but higher efficacy than bare-metal stents (BMS) in long femoropopliteal artery disease was tested.Although endovascular treatment of short superficial femoral (...) artery lesions revealed excellent results, efficacy in long lesions remains unsatisfactory.In a prospective, randomized, single-blind, multicenter study, 141 patients with symptomatic peripheral arterial disease were assigned to treatment with heparin-bonded, covered stents (Viabahn 72 patients) or BMS (69 patients). Clinical outcomes and patency rates were assessed at 1, 6, and 12 months.Mean ± SD lesion length was 19.0 ± 6.3 cm in the Viabahn group and 17.3 ± 6.6 cm in the BMS group. Major

2013 EvidenceUpdates PubMed

117. Heparin for assisted reproduction. (Full text)

Heparin for assisted reproduction. Heparin as an adjunct in assisted reproduction (peri-implantation heparin) is given at or after egg collection or at embryo transfer during assisted reproduction. Heparin has been advocated to improve embryo implantation and clinical outcomes.  It has been proposed that heparin enhances the intra-uterine environment by improving decidualisation with an associated activation of growth factors and a cytokine expression profile in the endometrium (...) that is favourable to pregnancy.To investigate whether the administration of heparin around the time of implantation (peri-implantation heparin) improves clinical outcomes in subfertile women undergoing assisted reproduction.A comprehensive and exhaustive search strategy was developed in consultation with the Trials Search Co-ordinator of the Cochrane Menstrual Disorders and Subfertility Group (MDSG). The strategy was used in an attempt to identify all relevant studies regardless of language or publication

2013 Cochrane PubMed

118. Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety

Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety TITLE: Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety DATE: 02 July 2013 CONTEXT AND POLICY ISSUES Low molecular weight heparins (LMWH) have emerged as an important alternative to unfractionated heparin (...) . LMWH are at least as effective antithrombotic drugs as UFH, however, it is still unclear whether the safety profiles of LMWH and UFH differ. 12 The important adverse events of heparin includes heparin-induced thrombocytopenia (HIT), an adverse drug reaction presenting as a prothrombotic disorder related to antibody-mediated platelet activation, 13 and bleeding. In 2009, CADTH published a review on the cost-effectiveness of LMWH compared with UFH. 11 It was reported in that review that LMWH appeared

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

119. Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. (PubMed)

Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. In the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear whether a once daily treatment regimen is as safe and effective as a twice daily treatment regimen. This is the second update of a review

2013 Cochrane

120. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. (Full text)

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit in microvascular

2013 Cochrane PubMed